You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 20, 2024

Investigational Drug Information for Ripasudil


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Ripasudil?

Ripasudil is an investigational drug.

There have been 12 clinical trials for Ripasudil. The most recent clinical trial was a Phase 3 trial, which was initiated on December 6th 2017.

The most common disease conditions in clinical trials are Fuchs' Endothelial Dystrophy, Corneal Dystrophies, Hereditary, and Cataract. The leading clinical trial sponsors are Kowa Research Institute, Inc., Case Western Reserve University, and Kaiser Permanente.

There are three US patents protecting this investigational drug and sixty-eight international patents.

Recent Clinical Trials for Ripasudil
TitleSponsorPhase
A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)Kowa Research Institute, Inc.Phase 3
A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)Kowa Research Institute, Inc.Phase 3
Study to Assess Safety and Tolerability of Multiple Doses of EO2002EmmecellPhase 1

See all Ripasudil clinical trials

Clinical Trial Summary for Ripasudil

Top disease conditions for Ripasudil
Top clinical trial sponsors for Ripasudil

See all Ripasudil clinical trials

US Patents for Ripasudil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ripasudil ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Ripasudil ⤷  Sign Up Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors BioAxone BioSciences, Inc. (Cambridge, MA) ⤷  Sign Up
Ripasudil ⤷  Sign Up Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors BioAxone BioSciences, Inc. (Boston, MA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ripasudil

Drugname Country Document Number Estimated Expiration Related US Patent
Ripasudil Australia AU2017261372 2036-05-05 ⤷  Sign Up
Ripasudil Canada CA3023278 2036-05-05 ⤷  Sign Up
Ripasudil China CN107847398 2036-05-05 ⤷  Sign Up
Ripasudil European Patent Office EP3452003 2036-05-05 ⤷  Sign Up
Ripasudil European Patent Office EP3981392 2036-05-05 ⤷  Sign Up
Ripasudil Hong Kong HK1249728 2036-05-05 ⤷  Sign Up
Ripasudil Japan JP2019520866 2036-05-05 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.